As ARKRAY transforms into a truly global diabetes brand, UK general manager David Eyre talks to Pathology in Practice about the challenge of setting up a new operation.
Apollo Project, we have lift off! These are the words from ARKRAY that signal its transformation from a technology driven company focusing on research and development into a globally recognised diagnostics brand.
The respected Japanese company, based in Kyoto and founded in 1960, initially built its success in domestic and Asian markets, where its reputation for excellence in customer service is surpassed only by product innovation in high-performance liquid chromatography (HPLC) and urinalysis. It has a long heritage of delivering innovative products that are straightforward, easy to use and reliable.
For many years ARKRAY relied on high-profile distributors to market its products in the USA, Europe and the UK. This needed to change. As David Eyre, the UK & Ireland general manager, explained: “Our focus is very clear and direct. It’s on improving the quality of life of our patients, first and foremost. And we can only do that if we engage directly with customers.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.